Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
WIPI-1 CRISPR/Cas9 KO Plasmid (h): sc-405215
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- WIPI-1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the WIPI-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: WIPI-1 Antibody (F-6): sc-376205
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
WIPI-1 CRISPR/Cas9 KO Plasmid (h) | sc-405215 | 20 µg | $397.00 |
Overview
WIPI1 encodes WIPI-1, a phosphatidylinositol 3-phosphate–binding WD-repeat protein that functions as a key effector of the class III PI3K complex during autophagosome biogenesis. WIPI-1 participates in early autophagy events by recruiting downstream ATG machinery to nascent phagophores and supporting membrane remodeling required for autophagosome maturation. Through its role in autophagy and cellular stress adaptation, WIPI-1 is relevant to pathways governing proteostasis, organelle quality control, and nutrient signaling. Dysregulation of autophagy components, including WIPI family proteins, has been associated with altered tumor cell survival, neurodegenerative processes, and inflammatory signaling in experimental models.
WIPI-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the WIPI1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the WIPI1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the WIPI1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish WIPI-1 protein expression.
This CRISPR knockout system enables efficient generation of WIPI1-deficient cell models for investigation of WIPI-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting WIPI1 exon(s) critical for WIPI-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple WIPI1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by WIPI-1 CRISPR/Cas9 KO Plasmid (h) and WIPI-1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the WIPI1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by WIPI-1 HDR Plasmid (h) and WIPI-1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by WIPI1 homology arms to support homology-directed repair at defined WIPI1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.